Immune responses included sustained mKRAS-specific CD4+ and CD8+ T cell subsets exhibiting favorable effector cytokine function, cytotoxic markers and memory phenotype, as well as antigen spreading to personalized tumor antigens beyond the immunizing antigens. This evidence concerns the gene CD8A and neoplasm.